Disc Medicine’s (IRON) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $170.00 price objective on the stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 118.00% from the stock’s current price.

A number of other equities analysts have also issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $149.00 target price on shares of Disc Medicine in a research report on Wednesday, October 21st. Truist Financial raised their price target on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. BMO Capital Markets lifted their price target on shares of Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $125.27.

View Our Latest Report on Disc Medicine

Disc Medicine Trading Up 1.8%

NASDAQ:IRON opened at $77.98 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 20.30 and a current ratio of 20.30. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The business’s 50-day simple moving average is $71.57 and its 200 day simple moving average is $71.05. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -12.30 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.10. As a group, sell-side analysts predict that Disc Medicine will post -6.20 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Jonathan Yu sold 8,796 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Savage sold 16,035 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $85.09, for a total value of $1,364,418.15. Following the transaction, the insider directly owned 63,445 shares of the company’s stock, valued at $5,398,535.05. This trade represents a 20.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 150,277 shares of company stock valued at $11,877,059 over the last quarter. Insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new stake in Disc Medicine in the second quarter worth $25,000. Allworth Financial LP acquired a new position in shares of Disc Medicine during the second quarter valued at $46,000. Sterling Capital Management LLC boosted its holdings in shares of Disc Medicine by 842.4% during the third quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock valued at $61,000 after acquiring an additional 834 shares during the period. Nykredit A S acquired a new position in shares of Disc Medicine during the second quarter valued at $103,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of Disc Medicine during the third quarter worth about $119,000. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.